Skip to main content

Advertisement

SpringerLink
Log in

How I Treat Blastomycosis

  • Current Management of Fungal Infections (L Ostrosky-Zeichner, Section Editor)
  • Published:
Current Fungal Infection Reports Aims and scope Submit manuscript

Abstract

Blastomyces dermatitidis, a dimorphic fungus endemic to the Midwestern, South Central and Northeastern United States, causes the disease blastomycosis. Aerosolized spores from the environment are inhaled into the lungs where primary infection may be asymptomatic or subclinical. Pneumonia, the most common presentation of symptomatic blastomycosis, can be acute, subacute or chronic. Cutaneous, osteoarticular, genitourinary or central nervous system involvement may result from extra-pulmonary dissemination. The Infectious Diseases Society of America has published treatment guidelines for blastomycosis Chapman (Clin Infect Dis 46:1801-1812, 2008). Oral itraconazole has been the mainstay of therapy for mild to moderate infection, while amphotericin B, or alternatively a lipid formulation, is reserved for more severe infection. Newer triazoles, such as voriconazole and posaconazole, have shown clinical potential and expand available treatment options.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. Cleary JH. A case of generalized blastomycosis. Cook County Hospital Reports. 1904: 293-299.

  2. Sarosi GA, Davies SF. Blastomycosis: state of the art. Am Rev Respir Dis. 1979;120:911–38.

    PubMed  CAS  Google Scholar 

  3. Chu JH, Feudtner C, Heydon K, Walsh TJ, Zaoutis TE. Hospitalizations for endemic mycoses: a population-based national study. Clin Infect Dis. 2006;42:822–5.

    Article  PubMed  Google Scholar 

  4. Crampton TL, Light RB, Berg GM, et al. Epidemiology and clinical spectrum of blastomycosis diagnosed at Manitoba hospitals. Clin Infect Dis. 2002;34:1310–6.

    Article  PubMed  Google Scholar 

  5. Meyer KC, McManus EJ, Maki DG. Overwhelming pulmonary blastomycosis associated with the adult respiratory distress syndrome. New Engl J Med. 1993: 1231-1236.

  6. Vasquez JE, Mehta JB, Agrawal R, Sarubbi FA. Blastomycosis in northeast Tennessee. Chest. 1998;114:436–43.

    Article  PubMed  CAS  Google Scholar 

  7. • Reed KD, Meece JK, Archer JR, Peterson AT. Ecologic niche modeling of Blastomyces dermatitidis in Wisconsin. PLOS One. 2008; 3: e2034. A fascinating look at the epidemiology of blastomycosis, including the effects of geography and climate, by experts in this field.

    Article  PubMed  Google Scholar 

  8. Klein BS, Vergeront JM, Weeks RJ, et al. Isolation of Blastomyces dermatitidis in soil associated with a large outbreak of blastomycosis in Wisconsin. New Engl J Med. 1986;314:529–34.

    Article  PubMed  CAS  Google Scholar 

  9. Pfister JR, Archer JR, Hersil S, et al. Non-rural point source outbreak near a yard waste collection site. Clin Med Res. 2011;9:57–65.

    Article  PubMed  CAS  Google Scholar 

  10. Dworkin MS, Duckro AN, Proia L, Semel JD, Huhn G. The epidemiology of blastomycosis in Illinois and factors associated with death. Clin Infect Dis. 2005;41(12):e107–11.

    Article  PubMed  Google Scholar 

  11. Hussein R, Khan S, Levy F, Mehta JB, Sarubbi FA. Blastomycosis in the mountainous region of northeast Tennessee. Chest. 2009;135:1019–23.

    Article  PubMed  Google Scholar 

  12. Graham Carlos W, Rose AS, Wheat LJ, et al. Blastomycosis in Indiana: digging up more cases. Chest. 2010;138:1377–82.

    Article  PubMed  Google Scholar 

  13. Farber ER, Leahy MS, Meadows TR. Endometrial blastomycosis acquired by sexual contact. Obstet Gynecol. 1968;32:1950199.

    Google Scholar 

  14. Kralt D, Light B, Cheang M, et al. Clinical characteristics and outcomes in patients with pulmonary blastomycosis. Mycopathologia. 2009;167:115–24.

    Article  PubMed  Google Scholar 

  15. Witorsch P, Utz JP. North American blastomycosis: a study of 40 patients. Medicine. 1968;47:169–200.

    Article  PubMed  CAS  Google Scholar 

  16. Chapman SW, Lin AC, Hendricks KA, et al. Endemic blastomycosis in Mississippi: epidemiological and clinical studies. Semin Respir Infect. 1997;12:219–28.

    PubMed  CAS  Google Scholar 

  17. Cherniss EI, Waisbren BA. North American blastomycosis: a clinical study of 40 cases. Ann Intern Med. 1956;44:105–23.

    PubMed  CAS  Google Scholar 

  18. Kaplan W, Clifford MK. Blastomycosis: a review of 198 collected cases in veterans administration hospitals. Am Rev Respir Dis. 1964;89:659–72.

    PubMed  CAS  Google Scholar 

  19. Pappas PG, Pottage JC, Powderly WG, et al. Blastomycosis in patients with the acquired immunodeficiency syndrome. Annals Intern Med. 1992;116(10):847–53.

    CAS  Google Scholar 

  20. Pappas PG, Threlkeld MG, Bedsole GD, et al. Blastomycosis in immunocompromised patients. Medicine. 1993;72(5):311–25.

    Article  PubMed  CAS  Google Scholar 

  21. Grim SA, Proia LA, Miller R, et al. A multicenter study of histoplasmosis and blastomycosis after solid organ transplantation. Transpl Infect Dis. 2012;14:17–23.

    Article  PubMed  CAS  Google Scholar 

  22. McCann DA, Smith HL. Infliximab associated Blastomyces dermatitidis in treatment of ulcerative colitis. Colorectal Dis. 2012, In press.

  23. Gruszka S. Associations of genetic variation and clinical characteristics of Blastomyces dermatitidis infections in Wisconsin. 2010. Accessed at http://www.minds.wisconsin.edu

  24. • Bariola J, Perry P, Pappas P et al. Blastomycosis of the central nervous system: a multicenter review of diagnosis and treatment in the modern era. Clin Infect Dis. 2010; 50: 797-804. The most comprehensive review of CNS blastomycosis to date.

    Article  PubMed  Google Scholar 

  25. Bradsher RW, Chapman SW, Pappas PG. Blastomycosis. Infect Dis Clin N Am. 2003;17:21–40.

    Article  Google Scholar 

  26. Harris JR, Blaney DD, Lindsley MD, et al. Blastomycosis in man after kinkajou bite. Emerg Infect Dis. 2011;17:268–70.

    Article  PubMed  Google Scholar 

  27. Lin MY, Chihara S, Smith KY, et al. Classic pyomyositis of the extremities as an unusual manifestation of Blastomyces dermatitidis: a report of two cases. Mycoses. 2010;53:356–9.

    PubMed  Google Scholar 

  28. Inoshita T, Youngberg GA, Boelen LJ, Langston J. Blastomycosis presenting with prostatic involvement: report of 2 cases and review of the literature. J Urol. 1983;130:160–2.

    PubMed  CAS  Google Scholar 

  29. Murray JJ, Clark CA, Lands RH. Reactivation blastomycosis presenting as a tubo-ovarian abscess. Obstet Gynecol. 1984;64:828–30.

    PubMed  CAS  Google Scholar 

  30. Saccente M, Woods GL. Clinical and laboratory update on blastomycosis. Clin Microbiol Rev. 2010;23:367–81.

    Article  PubMed  Google Scholar 

  31. Merz WG, Roberts GD. Algorithms for detection and identification of fungi. In Manual of Clinical Microbiology. Edited by Murray PR. Washington, DC: ASM Press; 1999; 1167-1183.

  32. Vyas KS, Bariola JR, Bradsher RW. Advances in the serodiagnosis of blastomycosis. Curr Fung Infect Rep. 2008;2:227–31.

    Article  Google Scholar 

  33. Durkin M, Witt J, LeMonte A, et al. Antigen assay with the potential to aid in diagnosis of blastomycosis. J Clin Microbiol. 2004;42:4873–5.

    Article  PubMed  Google Scholar 

  34. Connolly P, Hage CH, Bariola JR, et al. Blastomyces dermatitidis antigen detection by quantitative enzyme immunoassay. Clin Vaccine Immunol. 2011;19:53–6.

    Article  PubMed  Google Scholar 

  35. Wheat J, Wheat H, Connolly P, et al. Cross-reactivity in Histoplasma capsulatum variety capsulatum antigen assays of urine samples from patients with endemic mycoses. Clin Infect Dis. 1997;24:1169–71.

    Article  PubMed  CAS  Google Scholar 

  36. Sidamonidze K, Peck MK, Perez M, et al. Real-time PCR assay for identification of Blastomyces dermatitidis in culture and in tissue. J Clin Microbiol. 2012;50:1783–6.

    Article  PubMed  CAS  Google Scholar 

  37. • Chapman SW, Dismukes WE, Proia LA et al. Clinical practice guidelines for the management of blastomycosis: 2008 Update by the Infectious Diseases Society of America. Clin Infect Dis 2008; 46:1801-1812. This is an essential read for clinicians who manage blastomycosis and if only one article can be read, it should be this one. It provides a comprehensive overview of the treatment of blastomycosis.

    Article  PubMed  CAS  Google Scholar 

  38. Recht LD, Philips JR, Eckman MR, Sarosi GA. Self-limited blastomycosis: a report of thirteen cases. Am Rev Respir Dis. 1979;120:1109–12.

    PubMed  CAS  Google Scholar 

  39. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007;44:S27–72.

    Article  PubMed  CAS  Google Scholar 

  40. Dismukes WE, Bradsher RW, Cloud GC, et al. Itraconazole therapy for blastomycosis and histoplasmosis. Am J Med. 1992;93:489–97.

    Article  PubMed  CAS  Google Scholar 

  41. Itraconazole package insert. In: Ortho-McNeil-Janssen Pharmaceuticals, April 2008.

  42. Barone JA, Koh JG, Bierman RH, et al. Food interaction and steady state pharmacokinetics of itraconazole capsules in healthy male volunteers. Antimicrob Agents Chemother. 1993;37:778–84.

    Article  PubMed  CAS  Google Scholar 

  43. Stein AG, Daneshmend TK, Warnock DW, et al. The effects of H2-receptor antagonists on the pharmacokinetics of itraconazole, a new oral antifungal. Br J Clin Pharmacol. 1989;27:105–6.

    Google Scholar 

  44. Jaruratanasirikul S, Sriviriyajan S. Effect of omeprazole on the pharmacokinetics of itraconazole. Eur J Clin Pharmacol. 1998;54:159–61.

    Article  PubMed  CAS  Google Scholar 

  45. Barone JA, Moskovitz BL, Gaurnieri J, et al. Enhanced bioavailability of itraconazole in hydroxypropyl-ß-cyclodextrin solution versus capsules in healthy volunteers. Antimicrob Agnets Chemother. 1998;42:1862–5.

    CAS  Google Scholar 

  46. Li RK, Ciblak MA, Nordoff N, et al. In vitro activities of voriconazole, itraconazole, and amphotericin B against Blastomyces dermatitidis, Coccidioides immitis, and Histoplasma capsulatum. Antimicrob Agents Chemother. 2000;44:1734–6.

    Article  PubMed  CAS  Google Scholar 

  47. Poirier M, Cheymol G. Optimisation of itraconazole therapy using target drug concentrations. Clin Pharmacokinet. 1998;35:461–73.

    Article  PubMed  CAS  Google Scholar 

  48. Andes D, Pascual A, Marchetti O. Antifungal therapeutic drug monitoring: established and emerging indications. Antimicrob Agents Chemother. 2009;53:24–34.

    Article  PubMed  CAS  Google Scholar 

  49. Lestner JM, Roberts SA, Moore CB, et al. Toxicodynamics of Itraconazole: implications for therapeutic drug monitoring. Clin Infect Dis. 2009;49:928–30.

    Article  PubMed  CAS  Google Scholar 

  50. Saad AH, DePestel DD, Carver PL. Factors influencing the magnitude and clinical significance of drug interactions between azole antifungals and select immunosuppressants. Pharmacotherapy. 2006;26:1730–44.

    Article  PubMed  CAS  Google Scholar 

  51. Groll AH, Giri N, Petraitis V, et al. Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental Candida albicans infection of the central nervous system. J Infect Dis. 2000;182:274–82.

    Article  PubMed  CAS  Google Scholar 

  52. Lutsar I, Roffey S, Troke P. Voriconazole concentrations in the cerebrospinal fluid and brain tissue of guinea pigs and immunocompromised patients. Clin Infect Dis. 2003;37:728–32.

    Article  PubMed  Google Scholar 

  53. Johnson LB, Kauffman CA. Voriconazole: a new triazole antifungal. Clin Infect Dis. 2003;36:630–7.

    Article  PubMed  CAS  Google Scholar 

  54. Sugar AM, Liu XP. Efficacy of voriconazole in treatment of murine pulmonary blastomycosis. Antimicrob Agents Chemother 2001; 601-604.

  55. Freifeld A, Proia L, Andes D, et al. Voriconazole use for endemic fungal infections. Antimicrob Agents Chemother. 2009;53:1648–51.

    Article  PubMed  CAS  Google Scholar 

  56. Ta M, Flowers SA, Rogers PD. The role of voriconazole in the treatment of central nervous system blastomycosis. Ann Pharmacother. 2009;43:1696–700.

    Article  PubMed  CAS  Google Scholar 

  57. Pappas PG, Bradsher RW, Chapman SW, et al. Treatment of blastomycosis with fluconazole: a pilot study. The National Institute of Allergy and Infectious Diseases Mycoses Study Group. Clin Infect Dis. 1995;20:267–71.

    Article  PubMed  CAS  Google Scholar 

  58. Espinel-Ingroff A. Comparison of In Vitro Activities of the New Triazole SCH56592 and the Echinocandins MK-0991 (L-743,872) and LY303366 against Opportunistic Filamentous and Dimorphic Fungi and Yeasts. J Clin Microbiol. 1998;36:2950–6.

    PubMed  CAS  Google Scholar 

  59. Sugar AM, Liu XP. In vitro and in vivo activities of SCH56592 against Blastomyces dermatitidis. Antimicrob Agents Chemother. 1996;40:1314–6.

    PubMed  CAS  Google Scholar 

  60. Pascual A, Calandra T, Bolay S. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis. 2008;46:201–11.

    Article  PubMed  CAS  Google Scholar 

  61. • Smith J, Safdar N, Knasinski V et al. Voriconazole therapeutic drug monitoring. Antimicrob Agents Chemother. 2006; 50: 1570-1572. Any clinician who prescribes voriconazole will benefit from understanding its complicated pharmacokinetics and the necessity of TDM.

    Article  PubMed  CAS  Google Scholar 

  62. Krishna G, Ma L, Martinho M, O’Mara E. Single-dose phase I study to evaluate the pharmacokinetics of posaconazole in new tablet and capsule formulations relative to oral suspension. Antimicrob Agents Chemother. 2012;56:4196–201.

    Article  PubMed  CAS  Google Scholar 

  63. Nagappan V, Deresinski S. Posaconazole: a broad spectrum triazole antifungal agent. Clin Infect Dis. 2007;45:1610–7.

    Article  PubMed  CAS  Google Scholar 

  64. Krishna G, Moton A, Ma L, Medlock MM, McLeod J. Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. Antimicrob Agents Chemother. 2009;53:958–66.

    Article  PubMed  CAS  Google Scholar 

  65. Proia LA, Harnisch DO. Successful use of posaconazole for treatment of blastomycosis. Antimicrob Agents Chemother. 2012;56:4029.

    Article  PubMed  CAS  Google Scholar 

  66. Thompson GR, Wiederhold NP. Isavuconazole: a comprehensive review of spectrum of activity of a new triazole. Mycopathologia. 2010;170:291–313.

    Article  PubMed  CAS  Google Scholar 

  67. • Smith JA, Kauffman CA. Endemic fungal infections in patients receiving tumor necrosis factor-α inhibitor therapy. Drugs. 2009; 69: 1403-1415. A well-written overview of endemic mycoses associated with TNF antagonists and recommendations for management.

    Article  PubMed  CAS  Google Scholar 

Download references

Disclosure

No potential conflicts of interest were reported.

Author information

Authors and Affiliations

  1. Section of Infectious Diseases, Rush Medical College, 600 South Paulina Street, Suite 143 AAC, Chicago, IL, USA

    Laurie A. Proia

Authors
  1. Laurie A. Proia
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Laurie A. Proia.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Proia, L.A. How I Treat Blastomycosis. Curr Fungal Infect Rep 7, 21–28 (2013). https://doi.org/10.1007/s12281-012-0121-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12281-012-0121-y

Keywords

Search

Navigation